Explore 1P-LSD | PiHKAL · info

Exploring 1P-LSD. To explore a different substance…

Name

1P-LSD

IUPAC names

N,N-Diethyl-6-methyl-1-propanoyl-9,10-didehydroergoline-8β-carboxamide
(6aR,9R)-N,N-Diethyl-7-methyl-4-propanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(8β)-N,N-Diethyl-6-methyl-1-propanoyl-9,10-didehydroergoline-8-carboxamide

ID 5916 · Formula C₂₃H₂₉N₃O₂ · Molecular weight 379.495

InChI InChI=1S/C23H29N3O2/c1-5-21(27)26-14-15-12-20-18(17-9-8-10-19(26)22(15)17)11-16(13-24(20)4)23(28)25(6-2)7-3/h8-11,14,16,20H,5-7,12-13H2,1-4H3/t16-,20-/m1/s1

InChI Key JSMQOVGXBIDBIE-OXQOHEQNSA-N This stereoisomer Any stereoisomer

SMILES CCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C(=O)CC)CC

ChemSpider 52085129
PubChem 119025985
Wikipedia 1P-LSD
PsychonautWiki 1P-LSD
Project Response 1322-15
bluelight.org The Big & Dandy 1P-LSD-Thread Part 2
bluelight.org The Big & Dandy 1P-LSD Thread Part 1
forensicscienceeducation.org 1P-LSD
swgdrug.org 1P-LSD

Brandt, SD; Kavanagh, PV; Westphal, F; Stratford, A; Elliott, SP; Hoang, K; Wallach, J; Halberstadt, AL. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Test. Anal., 1 Sep 2016, 8 (9), 891–902. 1.8 MB. https://doi.org/10.1002/dta.1884

Brandt, SD; Kavanagh, PV; Twamley, B; Westphal, F; Elliott, SP; Wallach, J; Stratford, A; Klein, LM; McCorvy, JD; Nichols, DE; Halberstadt, AL. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test. Anal., 1 Feb 2018, 10 (2), 310-322. 1.2 MB. https://doi.org/10.1002/dta.2222

Brandt, SD; Kavanagh, PV; Westphal, F; Stratford, A; Elliott, SP; Dowling, G; Wallach, J; Halberstadt, AL. Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD). Drug Test. Anal., 13 May 2019, 11 (8), 1122-1133. 1.5 MB. https://doi.org/10.1002/dta.2613 #1P-LSD LC,MS,NMR,IR,UV

EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #22

Halberstadt, AL; Geyer, MA. Effect of hallucinogens on unconditioned behavior. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 159-199. 879 kB. https://doi.org/10.1007/7854_2016_466

Wagmann, L; Richter, LHJ; Kehl, T; Wack, F; Bergstrand, MP; Brandt, SD; Stratford, A; Maurer, HH; Meyer, MR. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal. Bioanal. Chem., 7 Jan 2019, n/a. 3.8 MB. https://doi.org/10.1007/s00216-018-1558-9 #11 MS

Grumann, C; Henkel, K; Stratford, A; Hermanns-Clausen, M; Passie, T; Brandt, SD; Auwärter, V. Validation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions. J. Pharm. Biomed. Anal., 1 Sep 2019, 174 270–276. 726 kB. https://doi.org/10.1016/j.jpba.2019.05.062 #1P-LSD LC,MS

Sexton, JD; Nichols, CD; Hendricks, PS. Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Front. Psychiatry, 11 Feb 2020, 10 n/a. 529 kB. https://doi.org/10.3389/fpsyt.2019.00896 #1P-LSD

Elliott, SP; Holdbrook, T; Brandt, SD. Prodrugs of new psychoactive substances (NPS): A new challenge. J. Forensic Sci., 13 Jan 2020, n/a. 815 kB. https://doi.org/10.1111/1556-4029.14268 #1P-LSD MS,UV

Halberstadt, AL; Chatha, M; Klein, AK; McCorvy, JD; Meyer, MR; Wagmann, L; Stratford, A; Brandt, SD. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD). Neuropharmacology, 1 Nov 2019, 107856. 923 kB. https://doi.org/10.1016/j.neuropharm.2019.107856 #1P-LSD

Brandt, SD; Kavanagh, PV; Westphal, F; Stratford, A; Odland, AU; Klein, AK; Dowling, G; Dempster, NM; Wallach, J; Passie, T; Halberstadt, AL. Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD). Drug Test. Anal., 16 Mar 2020, 12 (6), 812-826. 16.3 MB. https://doi.org/10.1002/dta.2789 #1P-LSD GC,LC,MS,NMR,IR

Grumann, C; Henkel, K; Brandt, SD; Stratford, A; Passie, T; Auwärter, V. Pharmacokinetics and subjective effects of 1P‐LSD in humans after oral and intravenous administration. Drug Test. Anal., 2 Jun 2020, 12 (8), 1144-1153. 784 kB. https://doi.org/10.1002/dta.2821 #1P-LSD

Tanaka, R; Kawamura, M; Hakamatsuka, T; Kikura-Hanajiri, R. Identification and analysis of LSD derivatives in illegal products as paper sheet. Yakugaku Zasshi, 1 Jan 2020, 140 (5), 739–750. 932 kB. https://doi.org/10.1248/yakushi.19-00230 #5 MS,NMR,UV,other

Tanaka, R; Kawamura, M; Hakamatsuka, T; Kikura-Hanajiri, R. Identification of LSD derivatives, 1cP-LSD, MIPLA and 1B-LSD in illegal products as paper sheet. Yakugaku Zasshi, 1 Nov 2020, 140 (11), 1405–1413. 606 kB. https://doi.org/10.1248/yakushi.20-00124 #9 MS,NMR,UV

Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT_1A, and 5-HT2_A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Sci. Int., 1 Dec 2020, 317 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #1P-LSD

1P-MIPLA

7 Dec 2019 · · Isomer Design